Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

ClinicalTrials.gov ID: NCT06637371

Public ClinicalTrials.gov record NCT06637371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.

Study identification

NCT ID
NCT06637371
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Amgen
Industry
Enrollment
21 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 15, 2024
Primary completion
Apr 9, 2027
Completion
Apr 9, 2027
Last update posted
Jun 16, 2026

2024 – 2027

United States locations

U.S. sites
15
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Orange County Research Center Lake Forest California 92630
Translational Clinical Research LLC Aventura Florida 33180
Destiny Research Center Palmetto Bay Florida 33157
ClinCept, LLC Columbus Georgia 31904
Chesapeake Clinical Research Inc White Marsh Maryland 21162
Brigham and Womens Hospital Boston Massachusetts 02115
Mayflower Clinical South Dartmouth Massachusetts 02747
Mayo Clinic Rochester Minnesota 55905
Prism Research LLC dba Nucleus Network Saint Paul Minnesota 55114
University of North Carolina Clinical and Translational Research Center Chapel Hill North Carolina 27599
Monroe Biomedical Research Monroe North Carolina 28112
North Carolina Clinical Research Raleigh North Carolina 27607
Allergy Asthma and Clinical Research Center Oklahoma City Oklahoma 73120
Monroe Biomedical Research North Charleston South Carolina 29406
Endeavor Clinical Trials San Antonio Texas 78240

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06637371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 16, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06637371 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →